← Back to patent-cliff list
177Lu-DOTA-EB-TATE
Tier C — Watch / trade177Lu-DOTA-EB-TATE
National Institute of Biomedical Imaging and Bioengineering
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Not applicable
Indications (approved)：Thyroid cancer, Nasopharyngeal carcinoma, Neuroendocrine tumour
Regional status
US
Phase II
2025-05-23
EU
-
China
No progress
2017-04-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 177Lu-DOTA-EB-TATE?
Approved indications include: Thyroid cancer, Nasopharyngeal carcinoma, Neuroendocrine tumour.
When does the 177Lu-DOTA-EB-TATE patent expire?
No public expiry year is available for 177Lu-DOTA-EB-TATE yet; this page updates once verified.
How do I get a quote for 177Lu-DOTA-EB-TATE intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02